Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot study to optimize eculizumab maintenance dose by body weight in adult aHUS
2019-001619-21Phase 4Active
- Sponsor
- Bellvitge Institute for Biomedical Research
- Start
- Jun 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of eculizumab in atypical hemolytic uremic syndrome (aHUS), sponsored by Bellvitge Institute for Biomedical Research. Primary endpoint: Recurrence rate of atypical hemolytic uremic syndrome. Started Jun 2019; status: active.
02
Drugs
eculizumab
03
Conditions
atypical hemolytic uremic syndrome (aHUS)
Beyond the preview
Go deeper on 2019-001619-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001619-21.